{
    "code": "06021434",
    "url": "http:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=06021434",
    "time": "2015-12-11 05:46:02",
    "許可證字號": "衛署醫器輸字第021434號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "109\/09\/07",
    "發證日期": "99\/09\/07",
    "許可證種類": "醫　器",
    "舊證字號": "",
    "醫療器材級數": "第三等級",
    "通關簽審文件編號": "DHA00602143400",
    "中文品名": "“考迪斯”普賽斯普羅鎳鈦支架系統",
    "英文品名": "“Cordis” Precise Pro Rx Nitinol Stent Systems",
    "效能": "Cordis Precise PRO RX鎳鈦支架系統系與Cordis ANGIOGUARD RX栓塞捕捉導引線系統併用，適用於治療必須接受頸動脈血管修復術，且頸動脈內膜切除術可能引發不良反應之高危險群病患，並須符合下列條件：1.有神經學症狀，且經超音波或血管攝影診斷為總頸動脈或內頸動脈狹窄 &#8805; 50%的病患，或沒有神經學症狀，但經超音波或血管攝影診斷為總頸動脈或內頸動脈狹窄 &#8805; 80%的病患，及2.病患目標病灶的血管直徑必須是4-9mm。目標病灶與血管末稍的距離必須在3mm至7.5mm之間，才能置入ANGIOGUARD RX栓塞捕捉導引線。",
    "醫器規格": "詳如中文仿單核定本",
    "劑型": "",
    "包裝": "",
    "醫器主類別一": "E心臟血管用裝置",
    "醫器次類別一": "E0001心血管支架",
    "醫器主類別二": "",
    "醫器次類別二": "",
    "醫器主類別三": "",
    "醫器次類別三": "",
    "主成分略述": "",
    "限制項目": [
        "02輸入"
    ],
    "申請商名稱": "1436801100  壯生醫療器材股份有限公司",
    "申請商地址": "台北市大安區敦化南路二段319號6樓",
    "主製造廠": {
        "製造廠名稱": "M460822300  CORDIS CORPORATION",
        "製造廠廠址": "14201 NW 60TH AVE. MIAMI LAKES, FL 33014 U.S.A.",
        "製造廠公司地址": "",
        "製造廠國別": "UNITED STATES",
        "製程": ""
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [],
    "仿單外盒": [
        {
            "title": "060214340001___20101012.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=06021434&Seq=001&Type=9"
        },
        {
            "title": "060214340002___20101012.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=06021434&Seq=001&Type=8"
        }
    ]
}